Why Inovio's Stock Is Trading Higher Today

Inovio Pharmaceuticals Inc INO is trading higher Thursday after the company announced it received regulatory authorization from Brazil's ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800, its DNA vaccine candidate for COVID-19.

The global Phase 3 segment of the Phase 2/3 clinical trial will evaluate the efficacy of INO-4800 in a two-dose regimen.

Inovio said the primary endpoint of the case-driven Phase 3 trial is virologically confirmed COVID-19.

"Inovio's focus on supporting the global response to the pandemic is unwavering – and will bring forward the potential advantages of INO-4800, which in addition to being well-tolerated with balanced neutralizing antibodies and T cell responses, has a strong thermostability profile and potentially offers the ability to serve as both a primary as well as a booster vaccine," said Joseph Kim, president and CEO of Inovio.

Inovio is a U.S.-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and other infectious diseases.

INO Price Action: Inovio has traded as high as $19 and as low as $5.81 over a 52-week period.

At last check Thursday, the stock was up 8.18% at $9.13.

Photo: courtesy of Inovio.